Innovation in pharmaceuticals is not possible without Research &
Development. Morepen driven by its passion for adhering to International
quality standards has created an excellent in-house R&D center, focused on
identifying and manufacturing high value added, complex new molecules for
introduction in the generic market.
Sophisticated, state-of-the art instruments like HPLC, GC, FTIR,
UV spectrophotometer are used for standardisation of manufacturing processes.
Key areas in which the company carries out R&D include:
Maximising utilisation of indigenous raw materials and imports substitution.
Development of novel drug delivery systems.
Development of products based on medicinal plants.
Development of safety and environment conservation methods.
Process and product development for existing and new products.
R & D Activities - Breaking fresh ground Patent
rules are being strengthened globally and there is urgent need of development
of non-infringing processes of bulk drugs to capture global market. MLL is
world leader as an approved generic supplier of Loratadine due to development
of non-infringing commercially viable and cost effective manufacturing
processes for the same. R&D scientists are involved in the development of
non-infringing process of Atorvastatin Calcium and Fluvastatin sodium
(Cholesterol lowering agents), Ramipril (an antihypertensive agent), Citalopram
hydrobromide (an anti depressant), Fexofenadine Hydrochloride (anti-allergic
product) and Pioglitazone Hydrochloride (An antidiabitic), which are at advance